Market & Regulation
Demis Hassabis on AGI and AI in Medicine
The Rundown AIhigh confidence
Why it matters
- →Hassabis's prediction sets a timeline for AGI, focusing research efforts.
- →AI's role in drug discovery could accelerate medical breakthroughs.
- →Philosophical applications of AI could redefine our understanding of reality.
Demis Hassabis, CEO of Google DeepMind, shared his insights on the future of Artificial General Intelligence (AGI) and AI's role in medicine. He anticipates AGI could be realized by 2030, though challenges like understanding world physics and memory remain. Hassabis sees AI as pivotal in drug discovery, with oncology and immunology as initial focus areas. He also envisions AI aiding in philosophical explorations about reality and human nature. This outlook underscores AI's potential to revolutionize both scientific research and philosophical understanding.
Read originalMore from The Rundown AI
More in Market & Regulation
© SiftedMarket & Regulationbusiness
Ex-Spotify Exec Uses AI to Evaluate Startups
Henrik Landgren, a former Spotify executive, is leveraging AI to help venture capitalists discern which startups are likely to succeed. By employing cohort analysis, Landgren's approach aims to identify startups that are not just hype. This method groups startups by shared characteristics to predict their potential success, offering a more data-driven approach to investment decisions. The initiative reflects a growing trend of using AI to bring more precision and objectivity to the venture capital industry. This could potentially shift how investments are made, focusing more on data-backed insights rather than intuition alone.
Sifted
© SiftedInvestment · $50M
Market & Regulationbusiness
Ex-DeepMind Team Raises $50M for AI Startup Inherent
Inherent, a new AI lab founded by former DeepMind researchers, has secured $50 million in funding to develop 'AI-native science.' This approach aims to integrate human scientific inquiry with advanced AI systems to foster novel discoveries. The startup's platform, Faraday, seeks to address the limitations of current AI by identifying which scientific questions are worth pursuing. With backing from Index Ventures and Radical Ventures, Inherent is poised to explore the intersection of AI and scientific research, potentially transforming how breakthroughs are achieved.
Sifted
© TechCrunch AIMarket & Regulationbusiness
Glean's Revenue Hits $300M Amid AI Cost-Cutting Demand
Glean has achieved a remarkable $300 million in annual recurring revenue, tripling its figures in just 15 months. This growth is particularly notable as the company faces new competition from tech giants like Google and Microsoft in the enterprise AI search market. Glean's edge lies in its 'context graph' technology, which enhances AI efficiency by reducing computing costs for enterprises. This feature is increasingly appealing to businesses aiming to manage their AI budgets more effectively. As the market becomes more crowded, Glean's ability to offer tailored AI solutions gives it a significant advantage. The company's revenue model, which includes both consumption-based and hybrid pricing, reflects its adaptability to client needs.
TechCrunch AI